AMRN

Healthcare Drug Manufacturers - General

Amarin Corporation plc

$12.35

-0.37 -2.91% today

Price History

Not enough data

Key Stats

Market Cap

258.97M

Avg Volume

66,614

EPS

-$1.20

52W High

$20.90

52W Low

$12.31

Div. Yield

0.0%

Analyst Ratings

Strong Sell

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

12.60

P/B Ratio

0.58

P/S Ratio

1.39

EV/EBITDA

2.21

EV/Revenue

-0.25

PEG Ratio

0.81

Margins

Gross Margin 42.0%

Operating Margin (28.4%)

Net Margin (14.6%)

EBITDA Margin (11.3%)

Growth & Returns

Revenue Growth (YoY)

(42.0%)

Return on Equity

(6.0%)

Return on Assets

(2.3%)

Liquidity & Leverage

Current Ratio

3.67

Quick Ratio

2.49

Debt / Equity

0.02

Total Cash

314.65M

Total Debt

7.17M

About

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.